StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$39.80+0.02 (+0.05%)

Close on Nov 13, 2026Market cap $40.48MP/E –Yield –

IRulya Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

IRulya Therapeutics's total debt was $0 at Sep 30, 2026. For fiscal 2025 it was $18.03M.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.03M–
FY2024Dec 31, 2024$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$0-100.0%
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0–
Q4 FY2025Dec 31, 2025$18.03M–
Q3 FY2025Sep 30, 2025$17.52M–
Q4 FY2024Dec 31, 2024$0–

More IRulya Therapeutics figures

See a number that looks wrong?